NCT06124560View on ClinicalTrials.gov

Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.

PHASE1CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

October 28, 2022

Primary Completion Date

November 7, 2022

Study Completion Date

November 7, 2022

Conditions
BioequivalenceDiabetes Mellitus, Type 2
Interventions
DRUG

Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet

The subjects randomly received single oral dose of Sitagliptin/Metformin HCl 100/1000 mg extended release film-coated tablet

Trial Locations (1)

66260

Avant Santé Research Center S.A. de C.V., San Pedro Garza García

Sponsors

Lead Sponsor

Galenicum Health
All Listed Sponsors
lead

Galenicum Health

INDUSTRY

NCT06124560 - Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions. | Biotech Hunter | Biotech Hunter